Cyclopharm Ltd (ASX: CYC) Share Price and News

Mr Heaney has also served as a Non-Executive Director of several non-listed companies. Mr Heaney has more than 40 years of experience in all aspects of wholesale banking and finance, received in general management roles with National Australia Bank Limited and subsidiary companies in both Australia and the US. He is also currently a member of the Risk Committee

Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. She has long been involved in path to market asset development and commercialization in these industries, notably including the clinical validation of therapeutics to create asset and company valuation uplift. Ms Angus has expertise in corporate strategy, stakeholder and investor engagement and innovative product development. In addition, she has experience in both governance and compliance in listed capital markets. She is a member of the Risk Committee.

Mr McBrayer has more than 35 years of experience in nuclear medicine, healthcare manufacturing, and regulated pharmaceutical businesses. Prior to Cyclopharm, Mr McBrayer was Managing Director of Lipa Pharmaceuticals, a contract manufacturer of over-the-counter healthcare products, where he led large-scale manufacturing, supply-chain, and regulatory operations serving domestic and international brands. Earlier in his career, he held senior management roles with Brambles Cleanaway, gaining experience in complex, asset-heavy service businesses, and with Syncor a provider of radioactive diagnostic and therapeutic pharmaceuticals, where he developed expertise in nuclear medicine logistics, regulatory compliance, and building global healthcare operations to include start-ups. He is a member of the Board Nominations Committee.

Mr Barrow has more than 20 years of experience in the healthcare industry, which includes numerous governance and senior executive roles. Mr Barrow is currently the Chief Executive Officer of The Benevolent Society, which provides integrated support services to children, young people, families and older Australians and carers. He was the Chief Executive Officer of Sydney North Health Network. The Sydney North Health Network is one of 31 Primary Health Networks established by the Australian Government to increase the efficiency and effectiveness of medical services for the community. He was the Chief Executive Officer of the Butterfly Foundation, Australia's national charity providing clinical services and support to address eating disorders and body image issues. He is a member of the Risk Committee.

Dr King has over 30 years of experience as a clinician, educator and researcher to the Cyclopharm board. Dr. King is Professor of Respiratory Medicine at the Northern Clinical School of the University of Sydney. He is also the Staff Specialist and Head of the Department of Respiratory and Sleep Medicine at Royal North Shore Hospital, where he directs the asthma service and is the Medical Director of the Respiratory Investigation Unit, and the Research Leader of the Airway Physiology and Imaging Group at the Woolcock Institute of Medical Research. In addition, Dr. King supervises PhD and other postgraduate students at the University of Sydney. Dr. King has a current clinical interest in the management of severe pulmonary embolism. His clinical expertise and research are in the mechanisms and management of airways diseases, such as asthma, COPD and bronchiolitis in haemopoietic stem cell transplant recipients, and in the effects of lung cancer surgery.

-

-